Antipodes Partners LTD Argenx Se Transaction History
Antipodes Partners LTD
- $3.16 Billion
- Q1 2025
A detailed history of Antipodes Partners LTD transactions in Argenx Se stock. As of the latest transaction made, Antipodes Partners LTD holds 327 shares of ARGX stock, worth $175,899. This represents 0.01% of its overall portfolio holdings.
Number of Shares
327
Previous 116
181.9%
Holding current value
$175,899
Previous $71,000
171.83%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ARGX
# of Institutions
498Shares Held
28.5MCall Options Held
330KPut Options Held
286K-
Price T Rowe Associates Inc Baltimore, MD5.38MShares$2.9 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.79MShares$1.5 Billion2.84% of portfolio
-
Janus Henderson Group PLC London, X02.14MShares$1.15 Billion0.73% of portfolio
-
Capital World Investors Los Angeles, CA1.94MShares$1.04 Billion0.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$664 Million11.83% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $29.8B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...